🇺🇸 US

PTGX revenue, net income and debt history (Protagonist Therapeutics, Inc)

Quick answer

Protagonist Therapeutics, Inc (PTGX) reported revenue of $46.0M and net loss of $130.1M for the fiscal year ended 2025-12-31, down 89.4% from $434.4M the year before, per its 10-K filed with the SEC on 2026-02-25.

✓ SEC EDGAR XBRL company facts (10-K/10-Q filings)

Data as of 2025-12-31. Source: SEC EDGAR XBRL company facts (10-K/10-Q filings)

Fiscal yearRevenueNet incomeLong-term debt
2025 (FY ending 2025-12-31)$46.0M-$130.1M—
2024 (FY ending 2024-12-31)$434.4M$275.2M—
2023 (FY ending 2023-12-31)$60.0M-$79.0M—
2022 (FY ending 2022-12-31)$26.6M-$127.4M—
2021 (FY ending 2021-12-31)$27.4M-$125.6M—
2020 (FY ending 2020-12-31)$28.6M-$66.2M—
2019 (FY ending 2019-12-31)$0.2M-$77.2M$9.8M
2018 (FY ending 2018-12-31)$30.9M-$38.9M—
2017 (FY ending 2017-12-31)$20.1M-$37.0M—
2016 (FY ending 2016-12-31)—-$37.2M—

Related

Last updated 2026-10-16. Data only, not financial or tax advice.